Reach Us +44-1904-929220
Current Research: Cardiology

Sign up for email alert when new content gets added: Sign up

Brent Klinkhammer MD, PharmD*
University of Nebraska Medical Center, Omaha, USA
*Correspondence: Brent Klinkhammer, MD, PharmD, University of Nebraska Medical Center, 982055 Nebraska Medical Center, Omaha, NE 68198-2055, USA, Tel: 218-261-0967, Email: [email protected]

Received Date: Oct 03, 2018 / Accepted Date: Oct 11, 2018 / Published Date: Oct 15, 2018

Citation: Klinkhammer B. Beta blocker use is associated with an improvement in intermediate overall survival after Transcatheter Aortic Valve Replacement (TAVR). Curr Res Cardiol 2018;5(3):34-7.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]


BACKGROUND: Despite initially concerns about their use, beta-adrenergic blockers (BB) have been associated with improved outcomes in patients with uncorrected aortic stenosis. However, the effect of beta blockers on outcomes after transcatheter aortic valve replacement (TAVR) is unknown.

PURPOSE: To elucidate the effect of beta blockers on patient-specific outcomes after TAVR.

METHODS: A retrospective cohort study of 339 consecutive patients who underwent a TAVR for severe aortic stenosis was performed to determine the effect of beta blockers on outcomes after TAVR.

RESULTS: Despite a greater prevalence of several significant comorbidities and a higher predicted surgical risk, beta-adrenergic blockers are associated with an improve in overall survival at 1 year (83% vs. 67%, p =0.0398). The use of beta blocker was also associated with a reduction of major adverse cardiovascular and cerebrovascular events in the short-term (30 days- 6 months) time period (23% vs. 39%, p =0.0208)

CONCLUSION: This study gives evidence to suggest that beta blockers are associated with an improvement of overall survival in the intermediate time period. This finding suggests that TAVR may be a compelling indication for use of a beta blocker.


Aortic stenosis; Transcatheter aortic valve replacement (TAVR); Myocardial infarction; Hypertension


Traditionally, beta-adrenergic blockers and other negative inotropic agents have been relatively contraindication in patients with severe aortic stenosis given concerns about reducing left ventricular contractility in the setting of fixed outlet obstruction. However, more recent studies have given evidence to suggest that beta blocker may not be contraindicated and possible even beneficial in patients with uncorrected aortic stenosis [1]. In a post hoc analysis published in JAHA in 2017, patients with asymptomatic aortic stenosis on beta blockers was strongly associated with a with lower risk of all-cause mortality and cardiovascular death. Furthermore, in an Italian study published by Rossi et al. beta blocker use was similarity associated with an all-cause reduction in mortality in patients who were initially evaluated as candidates for possible aortic valve replacement but were ultimately not felt to be candidates [2]. Taken together these studies suggest that the antiischemic and anti-cardiac remodeling properties of these agents have a role in the treatment of aortic stenosis.

Over much of the last decade, transcatheter aortic valve replacement (TAVR) has emerged as a viable option for nearly all patients with severe aortic stenosis in an attempt to enhance survival and quality of life. This advancement and widespread implementation of TAVR in previously medically unfit patients for surgical aortic valve patients raises questions about the potential role of beta blocker in patients following TAVR. It may be hypothesizing that the benefit of beta blocker in the post-TAVR arena may be even more beneficial than in patients with uncorrected aortic stenosis given the relief of obstruction from TAVR mitigates the major risk of using negative inotropes in these patients. To date, minimal research has been published to answer this important question and there also has been little data from surgical aortic valve replacement to guide potential research. However, in a recent published abstract by Alrifai et al. pre-operative beta blocker use did not improve the overall mortality [3]. Similarity, Lindman et al. found no survival benefit at 1 year in patients after TAVR [4]. In this trial, we aim to further characterize the impact of beta-adrenergic blockade on clinical outcomes following TAVR. We believe that beta blocker use could lead to similar improvements in overall survival to what has been documented in uncorrected aortic stenosis.

Patients and Methods

A single institution case-control study was conducted using data from large tertiary care referral center. We performed a retrospective chart review of 339 consecutive patients who underwent a transcatheter aortic valve replacement (TAVR) at Sanford Health in Fargo, ND from 8/10/2012 to 11/15/2016 for severe aortic stenosis, defined as an aortic valve area less than 1 cm2. The last date of data acquisition was 1/4/2017. The study population was divided in two cohorts based on whether or not they were taking a betaadrenergic antagonist at the time of TAVR. Patients not on a beta-blocker were assigned to the control cohort. Primary outcomes were overall survival at 1 month, 6 months, and 1-year post-TAVR. Secondary outcomes were procedural complications, major adverse cardiovascular and cerebrovascular events (MACCE) defined as death from any cause, myocardial infarction, rehospitalization, or stroke, cardiovascular mortality, myocardial infarction, stroke/TIA, heart failure exacerbation, or rehospitalization for any reason in defined time periods. Pre and postprocedural echocardiographic data were also compared. The clinical outcomes were assessed in accordance with the standardized endpoint definitions for TAVR of the Valve Academic Research Consortium-2 [5]. Heart failure exacerbation was defined as a gradual or rapid change in heart failure signs and symptoms resulting in a need for a change in therapy or hospitalization.

Informed consent was not required for inclusion in our retrospective study due to the nature of the study, and the absence of any direct interventions. This study protocol received dual IRB approval from the University of North Dakota IRB and from the Sanford Health IRB. The Fisher’s exact test was performed to determine statistical significance of categorical data and ANOVA was used to determine the statistical significance of continuous variables. All p-values were two-sided, and p-values < 0.05 were considered significant.


A total of 339 patients were included in the analysis. The baseline characterizes of both cohorts are given in Table 1.

Variables Beta-Blocker (n=250) Control (n=89) P-value
Age 79.2 (8.6) 79.0 (10.0) 0.8867
Male sex 57 (143) 51 (45) 0.3207
BMI 30.7 (6.1) 29.7 (6.7) 0.1919
Caucasian race 99 (247) 100 (89) 0.5696
EuroSCORE (%) 9.0 (6.3) 7.0 (5.7) 0.0105
Preprocedural HTN 91 (227) 80 (71) 0.0126
Preprocedural CAD 78 (194) 61 (54) 0.0032
Baseline Ejection Fraction <40% 16 (40) 10 (9) 0.2196
Preprocedural NYHA
Class III OR IV Symptoms
44 (111) 43 (38) 0.8047
Preprocedural DM 38 (96) 27 (24) 0.0028
Prior Stroke/TIA 12 (30) 10 (9) 0.7029
Preprocedural Atrial Fibrillation 34 (84) 21 (19) 0.0323
Preprocedural Serum Creatinine (mg/dL) 1.22 (0.64) 1.35 (1.26) 0.2243
Preprocedural eGFR < 60 mL/min 50 (126) 42 (37) 0.1746
Preprocedural Dyslipidemia 92 (231) 79 (70) 0.0013
Preprocedural AAA 13 (32) 6 (5) 0.0745
Preprocedural Carotid Artery Stenosis >50% or Prior CEA 28 (71) 25 (22) 0.5806
Preprocedural Symptomatic PAD 27 (68) 28 (25) 0.8904
Prior CABG 33 (83) 12 (11) 0.0001
Prior PCI 39 (97) 30 (27) 0.1614
Prior Permanent Pacemaker 14 (34) 8 (7) 0.1868
Prior Aortic Valvuloplasty 17 (43) 18 (16) 0.8715
Cardiovascular Pharmacology
ACE inhibitor 33 (83) 28 (25) 0.4275
Angiotensin II receptor blocker 16 (41) 21 (19) 0.3321
Calcium channel blocker 30 (76) 24 (21) 0.2746
Thiazide diuretic 17 (42) 30 (27) 0.0089
Loop diuretic 54 (135) 36 (32) 0.0044
Spironolactone 4 (11) 1 (1) 0.1957
Statin 73 (183) 62 (55) 0.0583
Aspirin 77 (192) 72 (64) 0.3898
Dual Antiplatelet Therapy 29 (72) 27 (24) 0.7854
Any anticoagulant 29 (72) 18 (16) 0.0493

Table 1: Baseline characteristics

There was a significantly higher burden of disease in the beta blocker cohort. Statistically significant differences were noted between the cohorts in terms of preprocedural coronary artery disease/prior CABG, hypertension, dyslipidemia, atrial fibrillation, and diabetes mellitus. There was also a significant increase in preprocedural EuroSCORE, indicating a higher surgical risk in the beta blocker cohort. Baseline and 1-year post-TAVR echocardiographic data for all cohorts is given in Table 2.

  Beta-Blocker Control P-value
Aortic valve area (VTI) (cm2) 0.88 (0.35) 0.84 (0.36) 0.3991
Peak aortic velocity (cm/s) 413.4 (66.3) 423.3 (61.2) 0.2228
Peak aortic gradient (mmHg) 70.3 (21.0) 73.8 (18.5) 0.1682
Mean aortic gradient (mmHg) 44.4 (13.0) 46.6 (11.9) 0.1621
Ejection fraction (%) 56.6 (13.0) 59.7 (11.8) 0.0526
Stroke volume (mL) 85.8 (19.1) 85.0 (23.0) 0.7756
Moderate aortic regurgitation (%) 19 (47) 21 (19) 0.6407
Severe aortic regurgitation (%) 2 (6) 6 (5) 0.1652
Moderate mitral regurgitation (%) 24 (59) 19 (17) 0.4598
Severe mitral regurgitation (%) 3 (8) 4 (4) 0.5215
1 year post-TAVR      
Aortic valve area (VTI) (cm2) 2.00 (0.59) 1.95 (0.67) 0.6848
Peak aortic velocity (cm/s) 220.8 (51.3) 213.4 (39.5) 0.4896
Peak aortic gradient (mmHg) 20.5 (10.1) 20.1 (10.0) 0.8358
Mean aortic gradient (mmHg) 11.4 (5.7) 12.6 (6.6) 0.3894
Ejection fraction (%) 57.7 (13.1) 59.6 (12.9) 0.4984
Stroke volume (mL) 94.9 (29.8) 84.5 (20.1) 0.1073
Moderate aortic regurgitation (%) 14 (16) 11 (3) 1.000
Moderate mitral regurgitation (%) 12 (14) 15 (4) 0.7473
Severe mitral regurgitation (%) 4 (4) 15 (4) 0.0407

Table 2: Echocardiographic data

There were no significant differences in any variable of interest at both baselines, but there was an increased incidence of severe mitral regurgitation in the control group. The TAVR procedural characteristics are present in Table 3.

  Beta-antagonist (n=250) Control (n=89) P-value
Transfermoral 82 (206) 79 (70) 0.4315
Transapical 14 (36) 15 (13) 1.000
Transaortic 2 (4) 3 (3) 0.3847
Trans-subclavian 1 (3) 3 (3) 0.0570
Transcaval 0 (1) 0 (0) 1.0000
Mean LOS after TAVR (days) 4.6 (7.6) 5.1 (5.6) 0.6055
Valve type
First generation Sapien 28 (69) 26 (23) 0.7831
Sapien XT 15 (38) 12 (11) 0.6004
Sapien S 32 (80) 38 (34) 0.2983
First Generation CoreValve 22 (56) 19 (17) 0.5519
CoreValve Evolute 3 (7) 4 (4) 0.4881
Mean valve size (mm) 26.1 (2.7) 25.6 (2.5) 0.0867

Table 3: Procedural characteristics

No differences were observed in regard to the TAVR approach, length of stay, valve size, or specific type of valve deployed. Finally, the primary and secondary outcomes of this study are presented in Table 4.

  Beta Antagonist Control P-value
% Survival > 1 month 94 (236/250) 94 (84/89) 1.0000
% Survival > 6 months 89 (182/204) 87 (58/67) 0.5165
% Survival > 1 year 83 (144/175) 67 (31/46) 0.0398
Periprocedural Major Vascular 8 (20) 10 (9) 0.5155
Periprocedural Minor Vascular 9 (23) 8 (7) 0.8296
Post-TAVR PPM implantation 9 (22) 6 (5) 0.4939
Periprocedural Increase in Serum Creatinine >1.5x baseline 5 (13) 7 (6) 0.5955
In Hospital      
MACCE 8 (20) 8 (7) 1.000
MI 1 (2) 0 (0) 1.000
Stroke/TIA 2 (5) 4 (4) 0.2493
HF exacerbation 20 (50) 25 (22) 0.3670
Discharge to 30 days      
MACCE 15 (36) 23 (19) 0.1343
Myocardial Infraction 1 (3) 1 (1) 1.000
Stroke/TIA 1 (2) 1 (1) 1.000
HF exacerbation 17 (40) 13 (11) 0.4887
Rehospitalization for any Reason 15 (36) 21 (18) 0.2358
30 days- 6 months      
MACCE 23 (43) 39 (24) 0.0208
Myocardial Infraction 1 (1) 4 (3) 0.0655
Stroke/TIA 3 (6) 0 (0) 0.3414
HF exacerbation 13 (24) 21 (13) 0.1491
Rehospitalization for any Reason 21 (39) 34 (21) 0.0586
6 months-1 year      
MACCE 45 (31) 32 (11) 1.000
Myocardial Infraction 3 (4) 0 (0) 1.000
Stroke/TIA 1 (2) 3 (1) 0.4706
HF exacerbation 21 (31) 12 (4) 0.2388
Rehospitalization for any reason 29 (42) 26 (9) 0.8538

Table 4: Primary and secondary outcomes

Beta blocker usage was associated with an improvement in overall survival after TAVR at 1 year, but not prior to that. Beta blocker use was also associated with a reduction in MACCE in the short term (30 days-6 month) timeframe.


In this study, we present evidence that contradicts previous published data and suggests that beta-adrenergic blockers are associated with improved intermediate overall survival, despite an increase in significant comorbidities and predicted surgical risk prior to this procedure. This study also indicates that beta blocker use is associated with a reduction in major adverse cardiovascular and cerebrovascular events in the short-term (30 days to 6 months post-TAVR) post-procedural period, which was driven mostly by a reduction in in the rehospitalization after TAVR. To our knowledge this study is the first to associated beat adrenergic blocker use with improved outcomes following TAVR. Consequently, this study also asserts the safety of beta blocker use in this clinical setting. Given these results, patients without clinical contraindications to beta adrenergic antagonists, TAVR may be a compelling indication for use of one of these agents to potentially improved post-procedural outcomes.

The mechanism by which beta blockers improve outcomes after TAVR is not specific known but given the delay in the onset of the survival benefit of beta blockers seen in this study it is reasonable to assume that the improvement in survival is secondary to the same beneficial mechanisms that beat blocker had in heart failure with reduced ejection fraction (HFrEF). Most notably the suppression of left ventricular remodeling by blocking the sympathetic activation is likely imperative in the improvement in survival, given that new or accelerated hypertension following TAVR is common and occurs in over half of all TAVR patients [6,7]. Furthermore, reduction in post-TAVR atrial and ventricular arrhythmias and the anti-ischemic effects of beta blocker also likely play a role in improving outcomes following TAVR and could conceivably fit with the timeline suggest in this study [8,9]. It is also significant that beta blocker use was not associated with any increase in heart failure exacerbations. This seems to suggest that implantation of a TAVR valve, may help to overcome the initial changes in inotropy that may occur following TAVR [10].

Despite these encouraging results, our study did not uncover any significant difference in ejection fraction, which has been documented in heart failure with reduced ejection fraction treated with beta blocker. There are multiple potential explanations for this including that TAVR has independently been associated with improvements in ejection fraction, reduction in preload following TAVR to a level that may not be optimal, and preexistent myocardial hypertrophy and fibrosis [5]. Furthermore, changes in mitral valve performance could also affect ejection fraction and cardiac output secondary to changes in left ventricle preload.

The study also gives preliminary data to suggest that beta blocker use in TAVR patient may also decrease the prevalence of moderate to severe mitral regurgitation. Previous studies have not found any similar reductions in the amount of regurgitation but have suggested other benefits such as a reduction in left ventricle workload, increased stroke volume, and improved overall survival [11,12]. This study was not specifically designed to quantify the clinical impact of the effect of beta blockers on mitral valve function in this study, but this is a potentially significant area for future research and may help to elucidate the mechanism by which beta blocker can improve outcomes following TAVR.

Finally, our study does have some limitations including its retrospective design, single center experience, and variability in the length of post-TAVR follow-up. There were several statistically significant differences in baseline characteristics. However, all of these characteristics seemingly fell in favor of the control group, and therefore are more likely to falsely reduce the true benefit of beta blockers rather than amplify it. This is most notably in the beta blocker cohort having a higher prevalence of preprocedural atrial fibrillation, which has clearly been associated with worse outcomes after TAVR [13]. On the other hand, some of the specific differences in baseline characteristics have not been specifically associated with worse outcomes after TAVR including a history of coronary artery disease and a history of coronary artery bypass graft surgery [14].


In this retrospective cohort study, association between the use of betaadrenergic antagonists and improvement in overall survival in patients after TAVR was found in the intermediate time frame. Beta blocker usage was also associated with a reduction in major adverse cardiovascular and cerebrovascular events in the short-term follow-up period. This study suggests that a history of TAVR may be an appropriate compelling indication for the use of beta blockers in an attempt to improve outcomes following TAVR.


The investigator would like to thank Thomas Haldis, DO and Cornelius Dyke, MD for their help in getting this project started, and Ronda Bolgrean, RN for her help with data acquisition.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.


Dr. Klinkhammer has no relationships with industry to disclose.